Replies to post #88324 on Savvy Trades and Investments

[researcher59]

NOVN has a borrow rate of 43% on IB, so yes it's in heavy demand by shorts. PUTs are not available so that's a factor. Maybe the shorts think the drug's lack of strong efficacy could hinder FDA approval or dampen eventual sales. I think it will get approved.